FDA Grants Accelerated Approval to Ukoniq for Previously Treated MZL and FL

The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti–CD20-based regimen and adults with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.